Trial Profile
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 27 Feb 2012 Actual initiation date changed from Jun 2004 to Aug 2004 as reported by ClinicalTrials.gov.
- 27 Feb 2012 Actual initiation date changed from Jun 2004 to Aug 2004 as reported by ClinicalTrials.gov.
- 27 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.